For breast cancer patients, is more frightening than the risk of breast cancer is the recurrence of breast cancer patients. Even in patients with early stage breast cancer, the risk of recurrence still exists, especially in the 1-3 years after operation. Therefore, the doctor will develop adjuvant therapy programs for patients in order to further reduce the risk of recurrence, and for hormone receptor-positive patients, adjuvant endocrine therapy process will be as long as five years or longer. ”
Breast cancer is a kind of estrogen in vivo with patients and other closely related tumors, and its occurrence and development of estrogen level and its metabolic abnormalities. The most commonly used endocrine treatment is by oral administration of related drugs, inhibit or reduce the secretion of estrogen and lower its standard. Comprehensive treatment of breast cancer, the postoperative adjuvant endocrine therapy is a very important component. Endocrine therapy or cessation of estrogen by blocking the production, eliminating the incentives to promote tumor growth.
Based on the current world’s largest and follow-up period of 100 months of adjuvant therapy for breast cancer clinical trials ATAC results showed that patients with breast cancer adjuvant endocrine therapy for anastrozole compared with tamoxifen use can further reduce the recurrence of breast cancer risk by 24% , contralateral breast newly issued 40% lower risk of breast cancer, distant metastasis risk reduction 16%. In addition, anastrozole in the overall safety and tolerability profile superior to tamoxifen in terms of, so including anastrozole, including third-generation aromatase inhibitors replace tamoxifen as postmenopausal hormone receptor-positive early breast cancer adjuvant endocrine the standard treatment program.
General early breast cancer with surgery the same day as the benchmark time, after the first and second recommended once every three months follow-up, third and fourth year of the proposed follow-up once every six months, from the fifth year for each year of follow-up period of time, until the life-long. According to the experience of Fudan University Cancer Hospital found that patients with breast cancer after a year lost to follow rate of 7%, 5 years will reach 37%, which for the long-term standard treatment in patients with breast cancer led to a very large obstacle.
